Diabetes Care, Vol 21, Issue 7 1062-1070, Copyright © 1998 by American Diabetes Association

ARTICLES

Glucose metabolism, lipid metabolism, and cardiovascular risk factors in adult Turner's syndrome. The impact of sex hormone replacement

CH Gravholt, RW Naeraa, B Nyholm, LU Gerdes, E Christiansen, O Schmitz and JS Christiansen
Department of Endocrinology M, University Hospital of Aarhus, Denmark. cg@afdm.aau.dk

OBJECTIVE: To examine glucose metabolism, blood pressure, physical fitness, and lipid metabolism in adult untreated women with Turner's syndrome compared with a group of normal women and to examine the effects of female sex hormone substitution on these factors. RESEARCH DESIGN AND METHODS: A total of 26 patients with Turner's syndrome were examined before and during sex hormone replacement with 17 beta-estradiol and norethisterone, and an age-matched control group (n = 24) was examined once. A frequently sampled intravenous glucose tolerance test was applied with minimal model assessment. We also performed an oral glucose tolerance test, measurement of 24-h ambulatory blood pressure, and assessment of physical fitness and lipid metabolism. RESULTS: Insulin sensitivity (SI) and glucose effectiveness (SG) were similar in Turner's syndrome patients and control subjects, whereas the acute insulin response (P = 0.03) was lower in Turner's syndrome patients, and no change was seen during sex hormone treatment. Abnormal glucose tolerance was found in 50% of Turner's syndrome patients before and 78% during treatment with sex hormones. Fat-free mass (FFM; P = 0.0005) and physical fitness (P = 0.002) were lower in Turner's syndrome subjects compared with control subjects. During treatment, an increase in FFM (P = 0.001) and physical fitness (P = 0.02) was seen in Turner's syndrome patients. Blood pressure was increased in Turner's syndrome, and a decrease was seen in diastolic blood pressure during treatment with sex hormones. CONCLUSIONS: Turner's syndrome is associated with glucose intolerance, diminished first-phase insulin response, elevated blood pressure, reduced FFM, and physical fitness. Sex hormone administration causes a deterioration in glucose tolerance, increases FFM and physical fitness, and has beneficial effects on blood pressure. The deleterious effect on glucose tolerance may be mediated by norethisterone, a gestagen known to have androgenic effects.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				N. Wooten, V. K. Bakalov, S. Hill, and C. A. Bondy Reduced Abdominal Adiposity and Improved Glucose Tolerance in Growth Hormone-Treated Girls with Turner Syndrome J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2109 - 2114. [Abstract] [Full Text] [PDF]

				B. E. Hjerrild, K. H. Mortensen, and C. H. Gravholt Turner syndrome and clinical treatment Br. Med. Bull., June 1, 2008; 86(1): 77 - 93. [Abstract] [Full Text] [PDF]

				K. Bolar, A. R. Hoffman, T. Maneatis, and B. Lippe Long-Term Safety of Recombinant Human Growth Hormone in Turner Syndrome J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 344 - 351. [Abstract] [Full Text] [PDF]

				C. H. Gravholt, H. E. Poulsen, P. Ott, J. S. Christiansen, and H. Vilstrup Quantitative liver functions in Turner syndrome with and without hormone replacement therapy Eur. J. Endocrinol., June 1, 2007; 156(6): 679 - 686. [Abstract] [Full Text] [PDF]

				C. A. Bondy and for The Turner Syndrome Consensus Study Group Care of Girls and Women with Turner Syndrome: A Guideline of the Turner Syndrome Study Group J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 10 - 25. [Abstract] [Full Text] [PDF]

				C. H. Gravholt, B. E. Hjerrild, L. Mosekilde, T. K. Hansen, L. M. Rasmussen, J. Frystyk, A. Flyvbjerg, and J. S. Christiansen Body composition is distinctly altered in Turner syndrome: relations to glucose metabolism, circulating adipokines, and endothelial adhesion molecules. Eur. J. Endocrinol., October 1, 2006; 155(4): 583 - 592. [Abstract] [Full Text] [PDF]

				K. Stochholm, S. Juul, K. Juel, R. W. Naeraa, and C. Hojbjerg Gravholt Prevalence, Incidence, Diagnostic Delay, and Mortality in Turner Syndrome J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3897 - 3902. [Abstract] [Full Text] [PDF]

				J-P Baguet, S Douchin, H Pierre, A-M Rossignol, M Bost, and J-M Mallion Structural and functional abnormalities of large arteries in the Turner syndrome Heart, November 1, 2005; 91(11): 1442 - 1446. [Abstract] [Full Text] [PDF]

				J. E. Ostberg, A. E. Donald, J. P. J. Halcox, C. Storry, C. McCarthy, and G. S. Conway Vasculopathy in Turner Syndrome: Arterial Dilatation and Intimal Thickening without Endothelial Dysfunction J. Clin. Endocrinol. Metab., September 1, 2005; 90(9): 5161 - 5166. [Abstract] [Full Text] [PDF]

				J. E. Ostberg, E. L. Thomas, G. Hamilton, M. J. H. Attar, J. D. Bell, and G. S. Conway Excess Visceral and Hepatic Adipose Tissue in Turner Syndrome Determined by Magnetic Resonance Imaging: Estrogen Deficiency Associated with Hepatic Adipose Content J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2631 - 2635. [Abstract] [Full Text] [PDF]

				J. E. Ostberg, M. J. H. Attar, V. Mohamed-Ali, and G. S. Conway Adipokine Dysregulation in Turner Syndrome: Comparison of Circulating Interleukin-6 and Leptin Concentrations with Measures of Adiposity and C-Reactive Protein J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2948 - 2953. [Abstract] [Full Text] [PDF]

				V. K. Bakalov, M. M. Cooley, M. J. Quon, M. L. Luo, J. A. Yanovski, L. M. Nelson, G. Sullivan, and C. A. Bondy Impaired Insulin Secretion in the Turner Metabolic Syndrome J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3516 - 3520. [Abstract] [Full Text] [PDF]

				Y. K. van Pareren, S. M. P. F. de Muinck Keizer-Schrama, T. Stijnen, T. C. J. Sas, and S. L. S. Drop Effect of Discontinuation of Long-Term Growth Hormone Treatment on Carbohydrate Metabolism and Risk Factors for Cardiovascular Disease in Girls with Turner Syndrome J. Clin. Endocrinol. Metab., December 1, 2002; 87(12): 5442 - 5448. [Abstract] [Full Text] [PDF]

				M. Elsheikh, D. B. Dunger, G. S. Conway, and J. A. H. Wass Turner's Syndrome in Adulthood Endocr. Rev., February 1, 2002; 23(1): 120 - 140. [Abstract] [Full Text] [PDF]

				C. H. Gravholt, B. Nyholm, B. Saltin, O. Schmitz, and J. S. Christiansen Muscle Fiber Composition and Capillary Density in Turner Syndrome: Evidence of increased muscle fiber size related to insulin resistance Diabetes Care, September 1, 2001; 24(9): 1668 - 1673. [Abstract] [Full Text] [PDF]

				P. Saenger, K. A. Wikland, G. S. Conway, M. Davenport, C. H. Gravholt, R. Hintz, O. Hovatta, M. Hultcrantz, K. Landin-Wilhelmsen, A. Lin, et al. Recommendations for the Diagnosis and Management of Turner Syndrome J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3061 - 3069. [Abstract] [Full Text] [PDF]

				C. H. Gravholt, J. Frystyk, A. Flyvbjerg, H. Orskov, and J. S. Christiansen Reduced free IGF-I and increased IGFBP-3 proteolysis in Turner syndrome: modulation by female sex steroids Am J Physiol Endocrinol Metab, February 1, 2001; 280(2): E308 - E314. [Abstract] [Full Text] [PDF]

				A. M. Rosenfalck, S. Maghsoudi, S. Fisker, J. O. L. Jørgensen, J. S. Christiansen, J. Hilsted, A. Vølund, and S. Madsbad The Effect of 30 Months of Low-Dose Replacement Therapy with Recombinant Human Growth Hormone (rhGH) on Insulin and C-Peptide Kinetics, Insulin Secretion, Insulin Sensitivity, Glucose Effectiveness, and Body Composition in GH-Deficient Adults J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4173 - 4181. [Abstract] [Full Text]

				M. Elsheikh, R. Bird, B. Casadei, G. S. Conway, and J. A. H. Wass The Effect of Hormone Replacement Therapy on Cardiovascular Hemodynamics in Women with Turner's Syndrome J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 614 - 618. [Abstract] [Full Text]

				T. C. J. Sas, S. M. P. F. de Muinck Keizer-Schrama, T. Stijnen, H. J. Aanstoot, and S. L. S. Drop Carbohydrate Metabolism during Long-Term Growth Hormone (GH) Treatment and after Discontinuation of GH Treatment in Girls with Turner Syndrome Participating in a Randomized Dose-Response Study J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 769 - 775. [Abstract] [Full Text]

				U. Querfeld, S. Döpper, A. Gradehand, P. Kiencke, F. Wahn, and H.-J. Zeisel Long-Term Treatment with Growth Hormone Has No Persisting Effect on Lipoprotein(a) in Patients with Turner's Syndrome J. Clin. Endocrinol. Metab., March 1, 1999; 84(3): 967 - 970. [Abstract] [Full Text]